Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28312360 | 0.83 | TSHR (0.39) | TSHR | |
| SCHEMBL4479106 | 0.78 | — | — | |
| SCHEMBL3336089 | 0.76 | LMNA (0.30) | — | |
| SCHEMBL1557272 | 0.76 | EGLN1 (0.43) | TSHR | |
| SCHEMBL2611784 | 0.73 | ALDH1A1 (0.48) | TSHR | |
| SCHEMBL24360329 | 0.72 | CYP2D6 (0.37) | TSHR | |
| SCHEMBL27383692 | 0.72 | TSHR (0.31) | TSHR | |
| SCHEMBL21357989 | 0.71 | TSHR (0.33) | TSHR | |
| SCHEMBL22113486 | 0.70 | EGLN1 (0.38) | TSHR | |
| SCHEMBL21811589 | 0.70 | CYP2D6 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662977-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | claimed |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SIGNALRX PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | PI4KA, PI4KB, PI4K2B | TSHR 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.